http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
배은영,Bae, Eun-Young 대한예방의학회 2008 예방의학회지 Vol.41 No.2
An economic evaluation is required in order to apply to the Health Insurance Review and Assessment Service (HIRA) for a listing in the national drug formulary. To assist companies in preparing the necessary documents, HIRA published guidelines for the economic evaluation of pharmaceuticals in 2006. The guidelines are composed of two parts: guidance and explanatory notes. Each guideline reflects the best practice which meets both the theoretical consensus within the academic community and local situations, like data availability. To enhance the transparency of evaluation, guidelines emphasize the reproducibility of data and analysis result. That is, all evaluation processes are required to be described in enough detail to be replicated by reviewers. With growing experience and theoretical development in this area, HIRA guidelines will be revised periodically.
협업필터링의 희박 행렬 문제를 위한 이행적 유사도 평가 모델
배은영(Eun-Young Bae),유석종(Seok-Jong Yu) 한국정보기술학회 2018 한국정보기술학회논문지 Vol.16 No.12
Collaborative filtering has been widely utilized in recommender systems as typical algorithm for outstanding performance. Since it depends on item rating history structurally, The more sparse rating matrix is, the lower its recommendation accuracy is, and sometimes it is totally useless. Variety of hybrid approaches have tried to combine collaborative filtering and content-based method for improving the sparsity issue in rating matrix. In this study, a new method is suggested for the same purpose, but with different perspective, it deals with no-match situation in person-person similarity evaluation. This method is called the transitive similarity model because it is based on relation graph of people, and it compares recommendation accuracy by applying to Movielens open dataset.
배은영(Eun-Young Bae),유석종(Seok-Jong Yu) 한국정보기술학회 2018 한국정보기술학회논문지 Vol.16 No.6
Recommender system is a system that recommends something that a person would like. Recommender systems are widely used and evolving in various fields such as Amazon product recommendation, Facebook or Linkedin friend recommendation, Netflix and Watcha movie recommendation, behavior based advertisement, news recommendation. In the academia, interest and research on recommender systems are steadily increasing, and the number of papers in this field is increasing year by year, and the field of research is becoming more and more fragmented and diversified. In this paper, we constructed a dataset based on dissertation data of recommender system obtained from IEEE Xplore Digital Library and ACM Digital Library, and proceeded with the analysis in order to grasp major research topics, application domains, preference techniques, and trends in research topics.
경제성평가자료제출생략 트랙으로 진입한 약제에 대한 외국의 치료적 이익 평가 결과 비교
배은영(Eun-Young Bae),차소희(Sohee Cha),임화령(Hwa-Ryeong Lim),이혜재(Hye-Jae Lee),홍지형(Jihyung Hong) 대한약학회 2024 약학회지 Vol.68 No.1
This study assessed the additional health benefits of the drugs listed through the Economic Evaluation Exemption Procedure (EEEP) in Korea. We conducted a comparative review of 32 EEEP drugs listed between May 2015 and July 2022, comparing how they were assessed in France, Germany, and Canada. To collect the data, we reviewed the evaluations conducted by the relevant agency in each country and identified if the additional benefit exists and how significant it is. Additionally, the size of the benefit gains assessed by each agency was categorized as “High” or “Low,” allowing us to evaluate the consistency among these countries. In France, only 38% of the 34 drugs compared demonstrated moderate or higher levels of additional benefit. Germany acknowledged substantial benefit improvement in 27% of the 30 drugs assessed, while 73% showed minor, unquantifiable, or no additional benefits. In Canada, 5 out of 22 cases have been identified as providing significant additional benefit. The level of inter-country consistency in the assessment results from these three countries was somewhat limited. Based on the evaluation results in France, Germany, and Canada, the additional benefits of EEEP drugs over existing treatments were not substantial in many cases. Even though the EEEP was introduced to improve accessibility to high-cost drugs for medical conditions with unmet needs, it is necessary to reconsider whether to allow exceptions for drugs with low therapeutic value.
의료기술평가를 통한 급여결정의 한계와 극복방안: 기등재의약품목록정비 사업에 대한 평가를 중심으로
배은영 ( Eun Young Bae ) 한국보건경제정책학회 2010 보건경제와 정책연구 Vol.16 No.3
Korea is among the countries which have experienced rapidly increasing drug expenditures. According to OECD health data, the annual growth rate of Korean drug expenditure was around 10% from 2001 to 2006. To control and keep this increase rate within sustainable levels, and attain the efficiency within the system, the Korean government announced the introduction of a positive list system in May 2006. Under the positive list system, only drugs which have established their value in terms of clinical efficacy and cost-effectiveness can be listed. In addition to new drugs, listed drugs have also been scheduled to have their value re-evaluated during the period from 2007 to 2012. Based on the evaluation results, existing drugs with low added value will be de-listed. The Health Insurance Review and Assessment Service(HIRA) has a mandate to review all listed drugs, and it reviewed migraine and hyperlipidemia drugs as a pilot project in 2007. Since HIRA opened its assessment reports and the preliminary decisions of the committee, there has been a debate over the assessment methodology and decisions made by the committee. This study will discuss the issues which have been raised in Korea during the re-evaluation of two therapeutics groups. These issues are: the relation between scientific assessment and decision making, the use of cost-effectiveness data in the determination of ceiling price, and the way social values are reflected in reimbursement decisions.
중증질환 치료제에 대한 급여정책을 둘러싼 윤리적 쟁점고찰
배은영 ( Eun Young Bae ),임민경 ( Min Kyoung Lim ),배승진 ( Seung Jin Bae ) 한국보건경제정책학회(구 한국보건경제학회) 2015 보건경제와 정책연구 Vol.21 No.1
본 연구는 중증질환에 대한 급여결정에 관여하는 여러 기준 중 질병의 중증도 기준을 중심으로 이를 둘러싼 윤리 원칙, 그리고 이를 뒷받침하는 실증연구 결과들을 살펴봄으로써 중증질환 급여정책의 방향을 점검하고자 하였다. 선행연구 고찰결과, 흔히 생각하는 것과 달리 치료하지 않을 경우의 기대 여명을 기준으로 자원배분의 우선순위를 부여하는 것은 이론적, 실증적 근거가 충분치 않아 보인다. 기대여명 못지않게 연령 요인이 중요하게 작용하며, 연령 요소와 기대여명을 모두 고려한 연구에서는 연령 요소가 더 큰 영향을 미치는 것으로 파악되었다. 하지만 연령요소를 별도로 고려하지 않았을 때에는 질환의 중증도가 높은 환자에 보건의료자원배분의 우선순위를 부여하는 경향이 있었다. 말기질환이나 암환자의 경우로 상황을 좀 더 구체화하면 많은 대규모 연구에서 말기라는 사실 때문에 더 큰 사회적 가치를 부여하는 것을 지지하지 않는 결과가 나타났다. 또한 질병의 중증도가 동일함에도 암이라는 이유만으로 더 큰 우선순위를 부여하지는 않는 것으로 나타났다. 현실의 의사결정이 보다 근거에 기반한 것이 되기 위해서는 중증도라는 개념으로 포괄적으로 접근하기보다 말기나 암과 같은 보다 구체적 조건에 대한 우리 사회 구성원들의 가치를 도출하는 노력들이 요구된다. This paper sought to explore the trends of rationing health care for very severe disease, by investigating the ethical principles and empirical analyses in setting priority based on disease severity. Contrary to the conventional belief, insufficient theoretical and empirical evidence was found regarding rationing health care based on life expectancy. Rather, not only life expectancy, but also the age of the patients significantly influence in setting priority, and age actually plays more critical role than life expectancy when both factors were considered simultaneously. However, when age was not considered separately, disease severity was substantially considered in setting priority; however, if we focus on patients with cancer of terminal disease, few studies suggested that “being terminally ill” or “having cancer” should have higher priority given disease severity are similar. Our study suggested that current “evidence-based decision making” should strive to derive public preferences on specific conditions such as terminal diseases or cancer, rather than handling “disease severity” as a general and inclusive term.